Navigation Links
ULURU Inc. Reports Second Quarter 2010 Financial Results
Date:8/17/2010

ADDISON, Texas, Aug. 17 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced its financial results for the second quarter ended June 30, 2010.

For the second quarter of 2010, the Company reported a net loss of $2.2 million, or $0.03 per share, compared with a net loss of $2.9 million, or $0.04 per share, for the same period last year.  For the six months ended June 30, 2010, the Company reported a net loss of $3.5 million, or $0.04 per share, compared with a net loss of $6.0 million, or $0.09 per share, for the same period last year.  At June 30, 2010, the Company held cash and cash equivalents of $1.7 million, compared with $1.9 million at December 31, 2009.

Commenting on the financial results Kerry P. Gray, President and CEO, stated, "In addition to the report of achievements during the second quarter, significant progress has been made in the marketing of Altrazeal® in the U.S.  Both internal and external sales forces have been expanded and Altrazeal® marketing has been focused on the major wound categories where we have developed strong clinical support, including diabetic foot ulcers, venous leg ulcers, and home healthcare.  We believe that benefits are now starting to be derived from our revised marketing strategy which will begin to be recognized in the second half of 2010.  We continue to evaluate ways to expand our sales marketing capabilities, including possible corporate collaborations.  The clinical data supporting Altrazeal® continues to demonstrate clinical advantages and cost benefits that clearly differentiate Altrazeal® from competitive products."

Mr. Gray added, "We were pleased to report the achievement of two important milestones during the second quarter, the Altrazeal® licensing agreement for China and the granting of the CE Mark.  With the granting of the CE
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... DUBLIN , June 1, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/qrmgrq/_analysis_of_the ) has announced the addition of ... Image Displays Market" report to their ... ,This report provides an in-depth analysis of ... revenue forecast, market shares, market dynamics, and ...
(Date:6/1/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced data ... in a Phase 1 investigator-sponsored study at the University ... presented at the 2015 American Society of Clinical Oncology ... Results from this study show a tolerable safety ... given intravenously.  Based in part on the ...
(Date:6/1/2015)... June 1, 2015 The Middle Eastern MRI systems ... which is replacing CT because of its higher sensitivity and ... one between the two available systems of MRI, open and ... top and bottom and do not enclose the patient in ... a study which shows that one in every 6 patients ...
Breaking Medicine Technology:Analysis of the US Medical Image Displays Market 2015-2017 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Middle East Open System MRI Market - Growth, Trends And Forecasts (2014 - 2019) 2
... the,symptoms of thyroid disease for another disorder such ... a new edition of a report from,Harvard Medical ... particularly in older men and women, that doctors ... focus on common,illnesses that occur with age, according ...
... /Xinhua-PRNewswire/ -- TaiGen Biotechnology,Inc. announces the successful completion ... clinical trial of Nemonoxacin (TG-873870) for,the treatment of ... have been admitted to the trial. Completion of ... quarter of 2007. In this trial, the effect,of ...
Cached Medicine Technology:You May Have a Thyroid Problem and Not Know It - Particularly If You're Over 60, Says a New Harvard Medical School Report 2TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP) 2
(Date:6/2/2015)... June 02, 2015 TheCelebrityDresses.com, a popular ... big discounts on their summer fashion cocktail dresses. The ... short dresses that would be suitable for a wide ... , TheCelebrityDresses.com designs and make high quality trendy ... they use include high quality satin, chiffon and cotton. ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The ... a study from the RSSearch® Patient Registry evaluating ... body radiotherapy (SBRT) for the treatment of centrally ... lung metastases. , The study, published in ... http://www.ro-journal.com/content/10/1/113/abstract ), included 111 patients with 114 centrally ...
(Date:6/2/2015)... Robert LaPrade, MD, PhD, Colorado Knee ... Research Institute, participated in the study “ When ... This was a collaborative project from the American Orthopaedic ... recently published in the American Journal of Sports Medicine. ... is evidence that early sport specialization may put young ...
(Date:6/2/2015)... Each year, Cosmetic Executive Women (CEW) awards ... year, the organization’s members – 8,000 industry experts – ... Beauty Quest Award at the 2015 Beauty Insiders’ Choice ... and 2-in-1 approach to skincare differentiated it amongst a ... consumer and professional fan bases, QVC has awarded Scalisi ...
(Date:6/2/2015)... 2015 SB 277 (CA Legislature, bit.ly/1Q0P8OY) ... to attend public or private school. SB277 cleared three ... the Appropriations Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). ... , “We believe that this bill affects the ... than it will (the) affect public health of California.. ...
Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2
... 8 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC ... pharmaceutical, medicinal and diagnostic products in China,today announced ... to,the Company,s Form 10KSB for the year 2006. ... Form 10QSB for the three, six and nine ...
... COMPANY REPORTS PROGRESS ON KEY INITIATIVES, RANCHO CORDOVA, ... a leading supplier of innovative products and,services that process, ... treatment of disease and injury, today reported results for,the ... quarter ended September 30, 2007, were $3.6 million,compared with ...
... OWINGS MILLS, Md., Nov. 8 Medifast, Inc.,(NYSE: ... the period ended,September 30, 2007. For quarter-ended September 30, ... from $19.6 million in the third,quarter of 2006. The ... share ($0.07 per diluted share), versus $1,455,000 or $0.11 ...
... ESAs can increase cancer growth, cause stroke and heart ... News) -- The U.S. Food and Drug Administration on ... erythropoiesis-stimulating agents, which are drugs used to treat certain ... Aranesp, Epogen and Procrit, and detail their dangers to ...
... N.J., Nov. 8 Wyeth (NYSE: WYE ),announced ... First Boston,Healthcare Conference on Tuesday, November 13, 2007 at ... M. Mahady, Senior Vice President,Wyeth and President, Wyeth Pharmaceuticals ... for investors at, http://www.wyeth.com and available for replay ...
... CLEVELAND, Nov. 8 Medical Mutual and Ohio ... to provide quality,affordable health insurance to OFBF,s more ... Farm Bureau members will gain access to,Medical Mutual,s ... hospitals and other medical service providers in Ohio. ...
Cached Medicine News:Health News:China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 3Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 4Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 5Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 6Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 2Health News:Medifast Announces Third-Quarter 2007 Results 3Health News:Medifast Announces Third-Quarter 2007 Results 4Health News:Medifast Announces Third-Quarter 2007 Results 5Health News:Medifast Announces Third-Quarter 2007 Results 6Health News:Medifast Announces Third-Quarter 2007 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 8Health News:FDA Issues New Warnings for Anemia Drugs 2Health News:FDA Issues New Warnings for Anemia Drugs 3Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 2Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 3
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
Pocket-sized instrument with fiber optic illumination. Swivelling viewing window with 3X magnification....
All metal construction with fiber optic illumination. Large diameter viewing port, insufflation port, and swivelling airtight window....
Medicine Products: